Indication
Mucopolysaccharidosis type I
**Mucopolysaccharidosis type I** (MPS I) is a rare, autosomal recessive lysosomal storage disease caused by mutations in the *IDUA* gene, leading to a deficiency of the enzyme alpha-L-iduronidase. Read more about Mucopolysaccharidosis type I
1 drugs 1 manufacturers
Drugs that treat it
Common Mucopolysaccharidosis type I therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soon**Mucopolysaccharidosis type I** (MPS I) is a rare, autosomal recessive lysosomal storage disease caused by mutations in the *IDUA* gene, leading to a deficiency of the enzyme alpha-L-iduronidase.
This enzymatic defect prevents the degradation of the glycosaminoglycans dermatan sulfate and heparan sulfate, resulting in their progressive accumulation within tissues and organs across the body.
Clinically, the disease spans a continuous spectrum ranging from severe disease (historically Hurler syndrome) to attenuated forms (historically Hurler-Scheie and Scheie syndromes).
Hallmarks include progressive multisystem involvement characterized by skeletal deformities (dysostosis multiplex), coarse facial features, hepatosplenomegaly, corneal clouding, cardiac valve disease, upper airway obstruction, and, in severe cases, neurocognitive decline and shortened lifespan.
- nih.gov
**Mucopolysaccharidosis type I** (MPS I) is a rare, autosomal recessive lysosomal storage disease caused by mutations in the *IDUA* gene, leading to a deficiency of the enzyme alpha-L-iduronidase This enzymatic defect prevents the degradation of the glycosaminoglycans dermatan sulfate and heparan sulfate, resulting in their progressive accumulation within tissues and organs across the body
- crisprmedicinenews.com
**Mucopolysaccharidosis type I** (MPS I) is a rare, autosomal recessive lysosomal storage disease caused by mutations in the *IDUA* gene, leading to a deficiency of the enzyme alpha-L-iduronidase
- medlineplus.gov
Clinically, the disease spans a continuous spectrum ranging from severe disease (historically Hurler syndrome) to attenuated forms (historically Hurler-Scheie and Scheie syndromes)
- nih.gov
Clinically, the disease spans a continuous spectrum ranging from severe disease (historically Hurler syndrome) to attenuated forms (historically Hurler-Scheie and Scheie syndromes)
- medlineplus.gov
Hallmarks include progressive multisystem involvement characterized by skeletal deformities (dysostosis multiplex), coarse facial features, hepatosplenomegaly, corneal clouding, cardiac valve disease, upper airway obstruction, and, in severe cases, neurocognitive decline and shortened lifespan
- ncdhhs.gov
Hallmarks include progressive multisystem involvement characterized by skeletal deformities (dysostosis multiplex), coarse facial features, hepatosplenomegaly, corneal clouding, cardiac valve disease, upper airway obstruction, and, in severe cases, neurocognitive decline and shortened lifespan
Personalize your experience
Follow Mucopolysaccharidosis type I and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.